Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies.

MLA

Wang, Bi-Cheng, et al. “Irinotecan plus Temozolomide in Relapsed Ewing Sarcoma: An Integrated Analysis of Retrospective Studies.” BMC Cancer, vol. 22, no. 1, Mar. 2022, p. 349. EBSCOhost, https://doi.org/10.1186/s12885-022-09469-5.

APA

Wang, B.-C., Xiao, B.-Y., & Lin, G.-H. (2022). Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies. BMC Cancer, 22(1), 349. https://doi.org/10.1186/s12885-022-09469-5

Chicago

Wang, Bi-Cheng, Bo-Ya Xiao, and Guo-He Lin. 2022. “Irinotecan plus Temozolomide in Relapsed Ewing Sarcoma: An Integrated Analysis of Retrospective Studies.” BMC Cancer 22 (1): 349. doi:10.1186/s12885-022-09469-5.